Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer.

Trial Profile

Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2011

At a glance

  • Drugs Paclitaxel (Primary) ; Sunitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2011 Planned End Date changed from 1 Dec 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 04 Jan 2011 Planned end date changed from 1 Sep 2015 to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 01 Mar 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top